Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

So better medical coverage for pharmaceuticals is really skewed toward better jobs ... we start to look at longevity and the ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Key Takeaways For Eli Lilly in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to its peers, indicating overvaluation. The low ROE, EBITDA, and gross profit suggest ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Size means little in light of this company's prospects.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks with consistent growth to buy. Currently, financial markets are experiencing a ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Here is what Baron Funds said about Eli Lilly and Company (NYSE:LLY) in its second-quarter 2024 investor letter. “Shares of global pharmaceutical company Eli Lilly and Company (NYSE:LLY ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...